We recently shared news of a promising diagnostic breath test presented at the 2023 World Conference on Lung Cancer held in October which may identify mesothelioma earlier and allow patients to seek treatment at the earliest possible stage.
And now, in February 2024, results from a clinical trial led by Professor Peter Szlosarek from the Centre for Cancer Cell and Molecular Biology in Barts Cancer Institute, suggest that an innovative treatment may improve the survival of mesothelioma patients and quadruple survival at 36 months when compared to placebo-chemotherapy.
As many lawyers who practice in this area witness, pleural mesothelioma has a drastically low survival rate when compared to other cancers. But this clinical trial has found that a combination treatment of chemotherapy with ADI-PEG20, a new drug, may offer better outcomes than we have seen in this area before.
The ATOMIC-meso trial is the outcome of over 20 years of work in which it was discovered that malignant mesothelioma cells do not contain a protein called ASS1 and so cannot produce arginine – meaning that their growth can be thwarted.
Any developments in the area of mesothelioma treatment are welcomed and it is so pleasing to be able to share the results of this trial and the new diagnostic test with newly diagnosed clients.
If you, a friend, or a family member have received a mesothelioma diagnosis, it’s vital to promptly seek guidance from a personal injury lawyer for a swift resolution to your claim.
Read Bree Knoester full bio here
Email
Bree Knoester
